Objectives: To compare choroidal vascularity index (CVI) measurements using the automated image binarization algorithm in healthy subjects with two Spectralis spectral-domain optical coherence tomography (SD-OCT) protocol scans.
Methods: Sixty-nine eyes of 69 healthy volunteers were included in this cross-sectional prospective study. Two subsequent horizontal 20°line scans passing through the fovea were acquired with enhanced-depth imaging mode with high speed (HS) and high resolution (HR) protocol scans. CVI and its subcomponents were measured with the previously validated automated algorithm. Differences between choroidal measurements obtained with HS and HR protocol scans were evaluated with t-test and Bland & Altman plots.
Results: A total of 33 male (47.8%) and 36 female (52.2%) subjects with a mean age of 35.1 ± 13.4 years were included. Overall, HS protocol scan was associated with significant lower values of total choroidal area (-0.047 mm) and stromal choroidal area (-0.036 mm), and a significant greater value of CVI (+0.010%) if compared to HR protocol. Luminal choroidal area was lower when calculated with the HS protocol, although it did not reach significance. To compare the two different protocols, the number of pixels should be multiplied for 3.87 ×5.73 when the CVI is measured on a HR OCT b scan and 3.87 ×11.46 for the HS OCT b scan.
Conclusions: HS and HR acquisition modes significantly influence CVI and its subcomponents values measured with the automated software. However, adopting the scale factors can minimize the differences between the two protocol scans.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275945 | PMC |
http://dx.doi.org/10.1038/s41433-022-02255-4 | DOI Listing |
Alzheimers Dement
December 2024
University of California San Francisco (UCSF), San Francisco, CA, USA; Northern California Institute for Research & Education (NCIRE), San Francisco, CA, USA; San Francisco Veterans Administration Medical Center (SFVAMC), San Francisco, CA, CA, USA.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has made many important contributions to the development of Alzheimer's Disease (AD) disease modifying treatments and diagnostic biomarkers. Since its funding in 2004 by the National Institutes of Aging, the goal of ADNI has been the validation of biomarkers for AD treatment trials. ADNI has enrolled over 2,400 participants in the USA and Canada for longitudinal clinical, cognitive, and biomarker studies.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: The National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) was developed to address the need for a brief yet comprehensive instrument to facilitate more uniform assessment in large-scale research studies. Here, we investigated whether the cognitive measures of the NIHTB detect cognitive decline in biomarker-confirmed Alzheimer's disease (AD).
Method: We used data from N = 178 participants (age 76.
Int J Clin Pediatr Dent
November 2024
Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.
Aim And Background: Glass ionomer cement (GIC) serves as a widely used restorative dental material, known for its direct bonding to tooth structures and fluoride-releasing properties. This study aims to investigate the enhancement of GIC through the incorporation of a green-mediated nanocomposite comprising chitosan, titanium, zirconium, and hydroxyapatite, with a focus on evaluating the wear resistance of the modified GIC.
Materials And Methods: A one-pot synthesis technique was utilized to prepare a green-mediated nanocomposite incorporating chitosan, titanium, zirconium, and hydroxyapatite nanoparticles.
Mediastinum
November 2024
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Thymoma is a rare mediastinal neoplasm originating from thymic epithelial cells, often associated with paraneoplastic syndromes. These syndromes can manifest as a range of autoimmune disorders, including myasthenia gravis, pure red cell aplasia, and aplastic anemia. Clinical trials involving the use of immune checkpoint inhibitors (ICIs) in thymoma have been complicated by a high incidence of immune-related adverse effects (irAEs).
View Article and Find Full Text PDFF S Rep
December 2024
Ferring Pharmaceuticals Inc., Parsippany, New Jersey.
Objective: To evaluate the current utilization of advanced practice providers (APPs) within the field of reproductive endocrinology and infertility.
Design: Cross-sectional.
Setting: Web-based.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!